Hanmi Pharmaceuticals spent the largest amount of money on research and investment in the first quarter of this year, according to reports submitted by top 10 Korean drugmakers.

Hanmi_한미약품 invested 37.3 billion won (33.1 million) in R&D in the first three months alone, which represents 21 percent of its sales.

According to the first-quarter financial reports of 10 largest pharmaceuticals, Dong-a ST, Green Cross_녹십자, ChungKunDang_종근당 and Ildong Pharmaceuticals_일동제약 also spent more than 10 percent of its sales on research and development. Dong-A ST_동아ST recorded 133 billion won in sales and invested 15.1 percent of it, 20 billion won, in R&D.

Green Cross poured 29.3 billion won (12.7 percent of sales) into R&D in Q1, while Daewoong Pharmaceuticals invested around 25.5 billion won (12.4 percent). ChungKunDang recorded 209.6 billion won in sales and spent 23.7 billion into R&D (11.3 percent). Ildong Pharmaceuticals, which received the approval for its new drug, Besivo Tab., invested 10.8 billion won (10.2 percent of Q1 sales).

Yuhan Corp._유한양행, which registered highest sales with 349.4 billion won in the first quarter, invested 7.1 percent (24.6 billion won) in R&D. Although it ranked No. 4 in R&D costs, investment did not exceed 10 percent of sales.

JW Pharmaceutical_중외제약, which recorded 123.2 billion won of sales, spent 8.1 billion into research (6.6 percent). Handok_한독약품’s investment did not exceed the 5 percent mark, standing at 4.9 billion won, or 4.8 percent of sales. Kwangdong Pharmaceutical_광동제약 ranked within the top 10 sales list but only spent 1 percent on research and development. Kwangdong marked 155.6 billion won of sales and spent 1.5 billion on R&D.

Green Cross poured 29.3 billion won (12.7 percent of sales) into R&D in Q1, while Daewoong Pharmaceuticals invested around 25.5 billion won (12.4 percent). ChungKunDang recorded 209.6 billion won in sales and spent 23.7 billion into R&D (11.3 percent). Ildong Pharmaceuticals, which received the approval for its new drug, Besivo Tab., invested 10.8 billion won (10.2 percent of Q1 sales).

Yuhan Corp., which registered highest sales with 349.4 billion won in the first quarter, invested 7.1 percent (24.6 billion won) in R&D. Although it ranked No. 4 in R&D costs, investment did not exceed 10 percent of sales.

JW Pharmaceutical, which recorded 123.2 billion won of sales, spent 8.1 billion into research (6.6 percent). Handok’s investment did not exceed the 5 percent mark, standing at 4.9 billion won, or 4.8 percent of sales. Kwangdong Pharmaceutical ranked within the top 10 sales list but only spent 1 percent on research and development. Kwangdong marked 155.6 billion won of sales and spent 1.5 billion on R&D.